Remember meForgot password?
    Log in with Twitter
Press Release

Cannabis Therapy Corp. Engages Nixon Peabody LLP for IP Protection

BOULDER, CO--(Marketwired - Jun 17, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company"), a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), has selected international law firm Nixon Peabody LLP to manage and protect its current and future intellectual property assets.

Nixon Peabody's legal team is led by Boston-based patents partner David Resnick who works with start-up and established companies, as well as major U.S. research institutions to develop comprehensive patent strategies to protect intellectual property. His focus is on strategic portfolio management, patent prosecution, transactional matters and associated client counseling. He manages the patent portfolios of some of the leading U.S. research institutions and domestic and international corporations. David also represents some of the world's most recognized life sciences corporations before the U.S. Patent and Trademark Office. He has extensive experience in the life sciences and has particular experience in the areas of pharmacogenomics, proteomics and disease biomarkers and their application in the evolving field of personalized medicine. David has written articles on patent prosecution practice, personalized medicine and technology issues for Nature Biotechnology, The Journal of Biolaw & Business, Personalized Medicine and other publications. He is also a member of the editorial board of Pharmaceutical Patent Analyst.

Cannabis Therapy Corp President & CEO Soren Mogelsvang states, "We are moving rapidly ahead in a sector where seemingly benign therapies such as fish oils can become billion dollar brands in very short order. We have no intention of underestimating the potential value that cannabinoids can mean to both the medical community and to the public at large. Nixon Peabody has strong experience in the pharmaceutical sector and in the development of new intellectual property and we look forward to working together to advance our business objectives."

For more information about the Company please visit and watch our corporate video at

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.


Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

For additional information, please contact:
Cannabis Therapy Corp. Investor Relations
T: +1 (800) 713-9091